BiotechTube
XL-protein

XL-protein

Freising, Germany· Est.
xl-protein.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

XL-protein is a privately held German biotech specializing in half-life extension technology. Its proprietary PASylation platform offers a biodegradable, polypeptide-based alternative to traditional PEGylation for improving therapeutic proteins. The company operates primarily as a platform and partnering business, out-licensing its technology for preclinical and clinical development across multiple disease areas, as evidenced by its recent license agreement with Grifols.

Drug Delivery

Technology Platform

PASylation® - a genetic fusion technology using a polypeptide chain of Proline, Alanine, and Serine (PAS) to extend the plasma half-life and improve the properties of therapeutic proteins. Marketed as a biodegradable, biological alternative to PEGylation.

Funding History

3
Total raised:$30M
Series B$20M
Series A$10M
GrantUndisclosed

Opportunities

The growing biologics and biobetters market creates strong demand for improved half-life extension technologies.
PASylation's biodegradable profile positions it well to capture market share from PEGylation, especially for chronic conditions requiring frequent dosing.
Strategic partnerships with large pharma companies can provide significant non-dilutive funding and validation.

Risk Factors

Competition from established (PEGylation) and novel half-life extension technologies is intense.
The company's success is heavily tied to the clinical and commercial success of its partners' programs, over which it has limited control.
As a small private firm, it faces financial constraints and dependency on the biotech funding climate.

Competitive Landscape

XL-protein competes in the half-life extension technology space against PEGylation (dominant), Fc fusion, albumin fusion, and other polypeptide-based technologies (e.g., XTEN, ELP). Its key differentiation is the biodegradability and potentially improved safety profile of its PAS polypeptide versus synthetic PEG polymers.

More companies in Germany →